These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25013997)

  • 41. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency.
    Peter F; Savoy C; Ji HJ; Juhasz M; Bidlingmaier M; Saenger P
    Eur J Endocrinol; 2009 Mar; 160(3):349-55. PubMed ID: 19074465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
    Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
    Cohen P; Rogol AD; Howard CP; Bright GM; Kappelgaard AM; Rosenfeld RG;
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
    Yuen K; Frystyk J; Umpleby M; Fryklund L; Dunger D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency.
    Kearns GL; Kemp SF; Frindik JP
    J Clin Endocrinol Metab; 1991 May; 72(5):1148-56. PubMed ID: 2022713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
    Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
    Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.
    Garcia JM; Polvino WJ
    Growth Horm IGF Res; 2009 Jun; 19(3):267-73. PubMed ID: 19196529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women.
    Kumagai Y; Hasunuma T; Padhi D
    Bone; 2011 Nov; 49(5):1101-7. PubMed ID: 21871589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.
    Yuen KC; Conway GS; Popovic V; Merriam GR; Bailey T; Hamrahian AH; Biller BM; Kipnes M; Moore JA; Humphriss E; Bright GM; Cleland JL
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2595-603. PubMed ID: 23585663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH.
    Hayakawa M; Shimazaki Y; Tsushima T; Kato Y; Takano K; Chihara K; Shimatsu A; Irie M
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1562-71. PubMed ID: 15070913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.
    Ashkenazi N; Rosenstock M; Hallak H; Bassan M; Rasamoelisolo M; Leuschner J; Shinar D
    Growth Horm IGF Res; 2016; 30-31():16-21. PubMed ID: 27552669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
    Toogood AA; Shalet SM
    J Clin Endocrinol Metab; 1999 Jan; 84(1):131-6. PubMed ID: 9920073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.